The type 2 diabetes drug dapagliflozin reduces the risk for worsening heart failure or death from cardiovascular disease among individuals with heart failure and reduced ejection fraction, whether or not they have diabetes, shows a study published in the New England Journal of Medicine.
A secondary analysis of results from the VISTA-16 trial suggests that serial hsCRP measurements may improve post-ACS risk stratification and help decrease subsequent CV events.
Close to 70% of hearts consented for donation in the US are never transplanted. A portable perfusion technology now under FDA review could significantly reduce that.
In patients hospitalized for heart failure, influenza was found to be an independent predictor of complications, extended stay, and death while in hospital.
Heart pumps may work just as well as heart transplants for older heart failure patients and complex cases, finds a study presented at the ISHLT annual meeting.
Statins decrease major vascular events like stroke and heart attack regardless of age. While the evidence is less robust for people over age 75, evidence suggest this age group may also benefit, a new study shows.
Adding a neprilysin inhibitor to an angiotensin receptor blocker may benefit patients hospitalized for acute heart failure more than an angiotensin receptor blocker alone, a study shows.
SGLT-2 inhibitors appear to have a more consistent effect on prevention of HF and renal outcomes than on atherosclerotic CV events, say study authors.
Cardiorenal syndrome has 5 subtypes that are each sbudivided as well. This quiz focuses on type 4--so cardiologists and nephrologists, unite!
In a new study, increased waist-to-hip ratio was shown to have a significant link to risk of death in heart failure.